Advertisement

Topics

Latest "Biosciences" News Stories

04:43 EDT 17th July 2019 | BioPortfolio

Here are the most relevant search results for "Biosciences" found in our extensive news archives from over 250 global news sources.

More Information about Biosciences on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biosciences for you to read. Along with our medical data and news we also list Biosciences Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biosciences Companies for you to search.

Showing "Biosciences" News Articles 1–25 of 1,100+

Wednesday 17th July 2019

Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome

Ann Arbor, Michigan July 16, 2019 – Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome. Arbor has an ongoing collaboration with the International Wheat Genome Sequencing Consortium (IWGSC), an international organization ded...


Tuesday 16th July 2019

Parvus Therapeutics Announces Key Executive and Board of Directors Appointments

-- Hugh Young Rienhoff, Jr., M.D., appointed as Chairman of the Board -- Charles A. Johnson, M.D., appointed to Board of Directors -- Alain Delcayre, Ph.D., appointed Senior Vice President of Research Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, toda...

Checkmate Pharmaceuticals Announces Appointment of Alan Fuhrman to Board of Directors

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, today announced the addition of Alan Fuhrman to its Board of Directors. “I am pleased to welcome Alan to our Board of Directors at this exciting time for our company. His experience as both an executive and Board member of several successful health ca...


Rising Biosciences Inc. Announces CBD Only Variant of Cannophen(TM) Begins Pilot Production Run, Coming to Market Soon

SANDUSKY, OH / ACCESSWIRE / July 16, 2019 / Rising Biosciences, Inc. (OTC Pink: RBII) (“Rising Biosciences” or the “Company”) is pleased to announce that a CBD only variant of Cannophen™ Capsules and Vape Cartridges has entered into an initial production run. Cannophen™ is Rising Biosciences’ flagship product. Cannophen™ oral capsules and vape cartridges have been developed using ...

LifeSpan BioSciences Announces the Acquisition of Everest Biotech

LifeSpan BioSciences (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Everest Biotech. Everest Biotech are ISO 9001:2015 certified experts in antigen affinity purified goat polyclonal antibodies. The acquisition of Everest Biotech further expands LSBio’s product offering and strengthens the company’s position as one o...

Monday 15th July 2019

Sanofi’s Alison Schecter Tapped as Selecta Bio Chief Medical Officer

Selecta Biosciences (NASDAQ: SELB) has appointed Alison Schecter to serve as chief medical officer. Schecter joins Watertown, MA-based Selecta from Sanofi (NYSE: SNY) where she was global project head in rare diseases. Her experience also includes positions at Baxalta, the Northeast J&J Innovation Center, and the Novartis Institutes of Biomedical Research. Lead Selecta drug candidate […]

Xenetic Bio submits updated prospectus for upcoming equity offering

A filing was made by Xenetic Biosciences raising the number of shares for its equity offering from the 1,555,555 in its preli -More- 

Sunday 14th July 2019

Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corporate update. “The first half of 2019 has been a period of transformation ...

Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia

BASKING RIDGE, N.J., July 15, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the European Medicines Agency (“EMA”) has granted Advanced Therapy Medicinal ...

Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer

WATERTOWN, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Alison Schecter, M.D., as Chief Medical Officer effective Monday, July 15, 2019. “Alison is an extrem...

Thursday 11th July 2019

IDT and 3CR collaborate on custom genotyping service

Integrated DNA Technologies (IDT) is teaming up with 3CR Bioscience to widen access to quality custom solutions for genotyping screening, in a partnership that fuses IDT’s oligo synthesis with 3CR’s PACE Genotyping Master Mix and expertise in designing assays. The collaboration will see researchers able to work with a combined technical service team to design and order custom PACE SNP assays....

Tizona Therapeutics Taps Joyson Karakunnel as Chief Medical Officer

Joyson Karakunnel has been appointed senior vice president and chief medical officer of Tizona Therapeutics. Karakunnel joins South San Francisco-based Tizona from Arcus Biosciences (NASDAQ: RCUS), which he was vice president and head of clinical development. Privately held Tizona is developing cancer immunotherapies. In January, the company received $105 million up front plus an equity […]

Proclara’s Suzanne Bruhn Named CEO of Tiaki Therapeutics

Suzanne Bruhn has been appointed CEO and president of Tiaki Therapeutics. She is also joining the Cambridge, MA, company’s board of directors. Bruhn succeeds interim CEO Barbara Tate, who will remain on the Tiaki board. Bruhn was most recently president and CEO of Proclara Biosciences. Her experience also includes roles at Promedior, Shire, and Cytotherapeutics. […]

Annexon Bio Brings On Rheos Exec Sanjay Keswani as Chief Medical Officer

Sanjay Keswani has left the president and CEO post at Rheos Medicines to become chief medical officer of Annexon Biosciences. Keswani’s experience also includes positions at Roche, Bristol-Myers Squibb (NYSE: BMY), and Eli Lilly (NYSE: LLY). In other moves, South San Francisco-based Annexon named Jennifer Lew chief financial officer and Lesley Stolz chief business officer. […]

Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019

Revises 2019 Full Year Revenue Guidance Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. The Company’s secon...

Neuromodulation start-up Saluda Medical completes $10mm Series B round

Neuromodulation start-up Saluda Medical Pty. Ltd. (spinal cord stimulation (SCS) device for pain and other CNS diseases) comp...

Agilent to Acquire BioTek, Strengthening Leadership Position in Growing Cell Analysis Segment

Highlights: Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis BioTek is a recognized leader for plate-readers and imaging systems with complementary offerings to Agilent’s portfolio Excellent growth potential; the acquisition positions Agilent well in the lar

Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients With Thin Cutaneous Melanoma Tumors

Study published recently in SKIN: The Journal of Cutaneous Medicine Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a study that establishes an evidence-based population to guide appropriate use of the DecisionDx®-Melanoma test in patients with thinner tumors. The stu...

Wednesday 10th July 2019

Aura gets global rights to Clearside's microinjector

Clearside Biomedical Inc. licensed Aura Biosciences Inc. global rights to use its Suprachoroidal Space Microinjector to deliv...

Curriculum Reforms in Uganda Integrate Modern Biosciences

Years of relentless efforts led by Uganda Biosciences Information Center (UBIC) to integrate modern biosciences into Uganda's middle/secondary schools' curriculum were finally rewarded. Uganda's Ministry of Education and Sports endorsed a new curriculum for agriculture course unit that requires students to be trained on modern biosciences including...

Hummingbird Bioscience Closes Extended Series A Financing To Advance Clinical Pipeline

SINGAPORE, July 10, 2019 /PRNewswire/ -- Hummingbird Bioscience, a Singapore founded biotech company focused on the discovery and development of novel antibody-based therapeutics, today announced the successful completion of an extended Series A financing round. The round was led by Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore. Hummingbird's existing inv...

Tiaki Therapeutics Appoints Suzanne Bruhn, PhD, as Chief Executive Officer

Tiaki Therapeutics, a company developing novel treatments to target the neuroinflammation that drives cognitive decline in patients with dementia, announced that Suzanne L. Bruhn, PhD, has been appointed as chief executive officer and president and joins the Board of Directors. Dr. Bruhn brings over 20 years of experience in executive leadership and drug development in the biopha

Aura, Clearside enter microinjector licensing deal

Aura Biosciences will use Clearside Biomedical's Suprachoroidal Space Microinjector technology with its ocular cancer drug ca -More- 

Fast track designation granted to Cellectar's CLR 131 candidate

Cellectar Biosciences' investigational candidate CLR 131, designed to treat relapsed or refractory diffuse large B-cell lymph -More- 

How to tell your synthetic biology story – with Ben Kellogg of BWK (The SynBioBeta Podcast)

In this episode, John Cumbers talks to Ben Kellogg about how to tell your synthetic biology story. Ben is the founder of BWK, an award-winning PR consulting firm representing clients like TED, MIT, Modern Meadow and Culture Biosciences. As the PR partner to TED’s Fellowship program, BWK works directly with the 400+ TED Fellows including […] The post How to tell your synthetic biology s...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks